TIGIT expression levels on CD4+ T cells are correlated with disease severity in patients with psoriasis

Abstract

Downregulation of TIGIT on CD4+ T cells may contribute to the pathogenesis of psoriasis, and activation of the TIGIT signalling pathway may be a potential therapeutic target.

TIGIT Can Exert Immunosuppressive Effects on CD8+ T Cells by the CD155/TIGIT Signaling Pathway for Hepatocellular Carcinoma In Vitro

“…Not surprisingly, therefore, the TIGIT/CD155 pathway inhibits the tumor-infiltrating CIK, NK, and CD4 + T cells. 37 – 39 However, CD155 expression in HCC cells has not been elucidated so far, and the role of CD155/TIGIT signaling on the CD8 + T cells infiltrating HCC tumors has also not been clearly defined. We found that CD155 was overexpressed in HCC compared with adjacent liver tissues, as well as in HCC cell lines such as SNU423, Hep3B, and Bel-7402.…”

The Emerging Jamboree of Transformative Therapies for Autoimmune Diseases

“…The alternative concept, namely agonizing immune inhibitory checkpoints, to treat AID has also been proposed in the literature in the past years (63, [98][99][100][101][102] and the efficacy of several coinhibitory agonists has been demonstrated preclinically in vitro using human peripheral blood mononuclear cells (PBMC) and in vivo using rodent models of AID (103)(104)(105)(106). Among others, B-and T-lymphocyte attenuator (BTLA/CD272) (107), lymphocyte-activation gene 3 (LAG-3/CD223) (107,108), T cell immunoglobulin and mucin-domain containing-3 (TIM-3) (107,108), T cell immunoreceptor with Ig and ITIM domains (TIGIT) (107)(108)(109)(110)(111)(112)(113)(114), PD1/PD-L1 (63, 101) and V-domain Ig suppressor of T cell activation (VISTA) (107,115,116) are emerging as very attractive target candidates for agonistic immune checkpoint intervention in AID.…”

Psoriasiform Dermatitis Related with T-Cell Immunoreceptor with Immunoglobulin and Immunoreceptor Tyrosine-Based Inhibitory Motif Domains Inhibitor in a Patient with Non-Small-Cell Lung Cancer

“…Although the pathological mechanisms of develop- ing psoriasiform dermatitis by TIGIT inhibitor are unknown, increased production of cytokines related to psoriasis could be one of the mechanisms 5 . Wang et al 5 reported about TIGIT+ CD4+ T-cells and cytokine levels in patients with psoriasis. The researchers reported that the activation of TIGIT inhibited psoriatic CD4+ T-cell proliferation, decreased the production of IFN-γ and IL-17A, and increased the IL-10 level 5 .…”

“…Wang et al 5 reported about TIGIT+ CD4+ T-cells and cytokine levels in patients with psoriasis. The researchers reported that the activation of TIGIT inhibited psoriatic CD4+ T-cell proliferation, decreased the production of IFN-γ and IL-17A, and increased the IL-10 level 5 . They also reported an increase in the production of IFN-γ and IL-17A subsequent to treatment with TIGIT inhibitor 5 .…”

“…The researchers reported that the activation of TIGIT inhibited psoriatic CD4+ T-cell proliferation, decreased the production of IFN-γ and IL-17A, and increased the IL-10 level 5 . They also reported an increase in the production of IFN-γ and IL-17A subsequent to treatment with TIGIT inhibitor 5 . We believe that downregulation of TIGIT on CD4+ T-cells might have contributed towards the pathogenesis of psoriasiform dermatitis in our case 5 .…”